This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (34) Citing Articles via Google Scholar Google Scholar Articles by Lindahl, B. Articles by Wallentin, L. Search for Related Content PubMed PubMed Citation Articles by Lindahl, B. Articles by Wallentin, L.

Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non–ST-segment elevation acute coronary syndromes

A Fragmin and fast Revascularisation during InStability in coronary artery disease (FRISC)-II substudy

Bertil Lindahl, MD, PhD^*,,*, Johan Lindbäck, MSc, Tomas Jernberg, MD, PhD, Nina Johnston, MD^*, Mats Stridsberg, MD, PhD, Per Venge, MD, PhD and Lars Wallentin, MD, PhD^*,

^* Department of Medical Sciences and Cardiology
Department of Medical Sciences and Clinical Chemistry
Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden

View larger version (17K): [in a new window]   Figure 1 (A) Box-plots showing plasma levels of NT-proB-type natriuretic peptide (NT-proBNP) at randomization, day 2, 6 weeks, 3 and 6 months in patients with measurements at all five occasions (p < 0.001). (B) Box-plots showing plasma levels of NT-proBNP at randomization, day 2, 6 weeks, 3 and 6 months in all patients with measurements of NT-proBNP (p < 0.001).

View larger version (23K): [in a new window]   Figure 2 Box plots showing plasma levels of NT-proB-type natriuretic peptide (NT-proBNP) at randomization, day 2, 6 weeks, 3 and 6 months in patients: 1) without elevation of cardiac troponin T (TnT); 2) with elevation of cardiac TnT, but without elevated C-reactive protein (CRP); and 3) with elevation of both cardiac TnT and CRP. URL = upper reference level.

View larger version (29K): [in a new window]   Figure 3 (A) Percentage of patients (n = 1,123) with left ventricular ejection fraction (LV-EF) below 0.45 estimated by echocardiography before discharge in relation to tertiles of the NT-proB-type natriuretic peptide (NT-proBNP) levels at randomization and tertiles of the percentage decrease of NT-proBNP from randomization to day 2. (B) Percentage of patients with Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 in the coronary arteries in patients randomized to the invasive strategy (n = 474) in relation to tertiles of the NT-proBNP levels at randomization and tertiles of the percentage decrease of NT-proBNP from randomization to day 2.

View larger version (14K): [in a new window]   Figure 4 (Left) Adjusted odds ratio (95% confidence interval) for death at two years for non–ST-segment elevation acute coronary syndromes patients with elevated NT-proB-type natriuretic peptide (NT-proBNP) in relation to when NT-proBNP is measured. The odds ratio applies to a doubling of NT-proBNP level at each time point (e.g., an NT-proBNP level at inclusion of 800 ng/l vs. 400 ng/l is associated with a 1.4-fold higher risk of subsequent death, compared with a 1.9-fold higher risk for a similar increase in NT-proBNP level at six months). Adjustment is made for age, gender, diabetes, previous myocardial infarction, creatinine level, ST-segment depression, cardiac troponin T, and C-reactive protein elevation. (Right) Mortality from time of blood sample to end of follow-up at two years in relation to two different cut-offs of NT-proBNP. HC = high cut-off: 1,000 ng/l; URL = upper reference level: 184 ng/l for men and 268 ng/l for women.